Clinical pharmacology of ponesimod, a selective S1P1 receptor modulator, after uptitration to supratherapeutic doses in healthy subjects.

Hoch, M; D'Ambrosio, D; Wilbraham, D; Brossard, P; Dingemanse, J

Hoch, M; D'Ambrosio, D; Wilbraham, D; Brossard, P; Dingemanse, J.

Afiliación

Hoch M; Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd., Allschwil, Switzerland. Electronic address: matthias.hoch@actelion.com.
D'Ambrosio D; Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd., Allschwil, Switzerland.
Wilbraham D; Quintiles Drug Research Unit at Guy's Hospital, London, United Kingdom.
Brossard P; Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd., Allschwil, Switzerland.
Dingemanse J; Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd., Allschwil, Switzerland.

Eur J Pharm Sci ; 63: 147-53, 2014 Oct 15.

Article en En | MEDLINE | ID: mdl-25046167

Asunto(s)

Receptores de Lisoesfingolípidos/metabolismo; Tiazoles/efectos adversos; Tiazoles/farmacología; Adolescente; Adulto; Anciano; Relación Dosis-Respuesta a Droga; Método Doble Ciego; Esquema de Medicación; Femenino; Humanos; Masculino; Persona de Mediana Edad; Tiazoles/administración & dosificación; Adulto Joven

Palabras clave

Heart rate reduction; Pharmacodynamics; Pharmacokinetics; Ponesimod; S1P(1) receptor modulator; Safety and tolerability

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Tiazoles / Receptores de Lisoesfingolípidos Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Pharm Sci Asunto de la revista: FARMACIA / FARMACOLOGIA / QUIMICA Año: 2014 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google